Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 21.96M | 29.95M | 43.09M | 39.24M | 29.19M |
Gross Profit | 5.19M | 4.73M | 20.24M | 18.43M | 7.99M |
EBITDA | -14.61M | -13.03M | 3.35M | 6.23M | -5.67M |
Net Income | -14.36M | -19.58M | 2.37M | 12.81M | -6.16M |
Balance Sheet | |||||
Total Assets | 40.98M | 48.88M | 69.21M | 64.92M | 48.90M |
Cash, Cash Equivalents and Short-Term Investments | 4.14M | 10.45M | 15.67M | 21.30M | 13.99M |
Total Debt | 4.41M | 2.93M | 3.70M | 4.17M | 1.79M |
Total Liabilities | 15.33M | 9.11M | 9.65M | 9.23M | 7.47M |
Stockholders Equity | 25.65M | 39.77M | 59.56M | 55.69M | 41.44M |
Cash Flow | |||||
Free Cash Flow | -8.32M | -5.16M | -988.11K | 5.99M | -286.79K |
Operating Cash Flow | -7.37M | -3.88M | 572.55K | 6.47M | 249.19K |
Investing Cash Flow | -1.04M | -1.28M | -1.56M | -733.47K | -535.98K |
Financing Cash Flow | 2.30M | -451.81K | 720.50K | 1.09M | 1.90M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
75 Outperform | $3.23B | 87.83 | 2.04% | 1.63% | -3.98% | -93.50% | |
70 Outperform | $163.51M | 21.88 | 14.06% | ― | 15.71% | 15.03% | |
63 Neutral | $255.14M | 20.00 | 3.67% | 8.63% | -1.36% | -54.97% | |
63 Neutral | $16.78B | 10.88 | -7.08% | 3.04% | 1.73% | -25.15% | |
50 Neutral | $145.99M | ― | -0.45% | ― | -6.12% | -105.56% | |
40 Underperform | $16.23M | ― | 89.94% | ― | 3.11% | 11.94% | |
38 Underperform | $720.63K | ― | ― | ― | ― |
On June 24, 2025, Charles & Colvard entered into a Convertible Secured Note Purchase Agreement with Ethara Capital LLC for $2.0 million, structured in two tranches. This agreement grants Ethara Capital the right to appoint directors and observers to Charles & Colvard’s board, while the company secures the note with its assets. The deal, subject to shareholder approval, allows for conversion into common stock and includes waivers of severance benefits by the company’s CEO and CFO, indicating a strategic move to strengthen its financial position and governance.
Charles & Colvard, Ltd. announced that its common stock will be delisted from the Nasdaq Stock Market due to non-compliance with the timely filing of financial reports. The company has decided not to appeal this decision, and trading will be suspended on April 25, 2025. Following the delisting, the company’s stock is expected to be quoted on the OTC Experts Market, although there is no assurance of an active trading market.